{"id":"ba09f92a-6b85-47e0-9264-25e22bd2c8f1","modelId":"1ede4325-d956-495d-b01b-3e5ffad096a9","versionId":null,"locationId":"2d9f173e-2c18-4049-9bfa-cfd511918daa","operatorId":"fffa2127-5d46-4965-b510-cf96161154f0","ownerId":null,"slug":"histosonics-edison-newport-beach-california-usa","status":"operational","firstSeen":"2024-01-01T00:00:00.000Z","statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":["surgical_assistance"],"shiftStructure":null,"hoursPerDay":8,"siteType":"hospital","operatorConfirmed":null,"humanSupervisionOnsite":null,"locationPrecisionTier":"city_centroid","deploymentScale":"medium_11_100","siteEnvironment":"indoor","operatorType":null,"sourceQualityTier":2,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://histosonics.com/find-edison-provider/","name":"HistoSonics","title":"Find a Provider - HistoSonics"}],"notes":"Hoag Memorial Hospital Presbyterian, Interventional Radiology, in Newport Beach listed as an active Edison provider.","keyFacts":[],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":"healthcare","scaleTier":"commercial_10_99","contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-08-08T22:33:05.405Z","updatedAt":"2026-08-21T14:23:17.339Z","model":{"id":"1ede4325-d956-495d-b01b-3e5ffad096a9","companyId":"fffa2127-5d46-4965-b510-cf96161154f0","modelName":"Edison Histotripsy System","slug":"histosonics-edison","description":"Robotic, image-guided focused ultrasound (histotripsy) platform that mechanically destroys and liquefies targeted tumors non-invasively without incisions. Uses a robotic arm to deliver focused ultrasound energy. First and only histotripsy platform cleared for clinical use globally.","formFactor":"surgical","industryVertical":"healthcare","environment":"indoor","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"},{"url":"https://histosonics.com/our-technology/","title":"Our Technology","sourceName":"HistoSonics"},{"url":"https://histosonics.com/fda-awards-histosonics-clearance-of-its-first-of-a-kind-edison-histotripsy-system-2/","date":"2023-10-09","title":"FDA Awards HistoSonics Clearance of its Edison Histotripsy System","sourceName":"HistoSonics"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"FDA clearance","value":"De Novo 2023 (liver tumors)"},{"label":"Type","value":"Robotic histotripsy / focused ultrasound"},{"label":"Maturity","value":"Commercial / FDA-cleared"},{"label":"Applications","value":"Liver tumors (cleared), kidney (pending), pancreatic (planned)"},{"label":"Non-invasive treatment","value":"HistoSonics says the Edison Histotripsy System delivers pulsed sound energy without needles or incisions and mechanically destroys targeted liver tumors at the sub-cellular level (Our Technology)."},{"label":"Physician monitoring","value":"HistoSonics says physicians continuously monitor the treatment effect and control the Edison system in real time (Our Technology)."}],"createdAt":"2026-07-23T13:40:39.557Z","updatedAt":"2026-10-12T21:51:25.812Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":"supervised","autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"fffa2127-5d46-4965-b510-cf96161154f0","name":"HistoSonics","slug":"histosonics","description":"Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.","status":"private","founded":2009,"hq":"Plymouth, MN, USA","hqLat":45.0065149,"hqLng":-93.46651,"hqGeocodedAt":"2026-08-05T14:32:55.061Z","hqAddress":null,"hqPrecision":null,"website":"histosonics.com","fundingTotal":"102000000","type":"hardware","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":75,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"},{"url":"https://histosonics.com/histosonics-secures-102m-series-d-financing/","title":"HistoSonics Secures $102M Series D Financing","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-stake-acquired-2b-investor-syndicate/","title":"HistoSonics stake acquired by $2B investor syndicate","sourceName":"MassDevice"},{"url":"https://www.businesswire.com/news/home/20250807749442/en/HistoSonics-Announces-%242.25B-Acquisition-by-Consortium-of-Top-Tier-Investors","title":"HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors","sourceName":"Business Wire"}],"keyFacts":[{"label":"HQ","value":"Plymouth, Minnesota, USA"},{"label":"Founded","value":"2009"},{"label":"CEO","value":"Mike Blue"},{"label":"Product","value":"Edison Histotripsy System, non-invasive focused ultrasound for tumor destruction."},{"label":"FDA","value":"De Novo authorization for liver tumors, Oct 2023; kidney indication pending."},{"label":"CE Mark (reported, Jul 2026)","value":"CE Mark granted."},{"label":"Ownership (Aug 2025)","value":"Management-led majority stake bought by K5 Global, Bezos Expeditions, Wellington; valued ~$2.25B."},{"label":"Funding (reported, unconfirmed)","value":"$102M+ Series D led by Alpha Wave Ventures."},{"label":"Valuation (reported, 2026)","value":"$3.75B"},{"label":"Investors","value":"Alpha Wave Ventures, Amzak Health, HealthQuest Capital, J&J Innovation."}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-23T13:40:08.115Z","updatedAt":"2026-10-21T00:50:33.687Z"}},"version":null,"location":{"id":"2d9f173e-2c18-4049-9bfa-cfd511918daa","name":"Hoag Memorial Hospital Presbyterian","slug":"newport-beach-california-usa","kind":"hospital","parentLocationId":null,"region":"California","lat":33.6234445,"lng":-117.9296041,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-08-08T22:33:05.014Z","updatedAt":"2026-08-09T04:26:19.821Z"},"operator":{"id":"fffa2127-5d46-4965-b510-cf96161154f0","name":"HistoSonics","slug":"histosonics","description":"Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.","status":"private","founded":2009,"hq":"Plymouth, MN, USA","hqLat":45.0065149,"hqLng":-93.46651,"hqGeocodedAt":"2026-08-05T14:32:55.061Z","hqAddress":null,"hqPrecision":null,"website":"histosonics.com","fundingTotal":"102000000","type":"hardware","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":75,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"},{"url":"https://histosonics.com/histosonics-secures-102m-series-d-financing/","title":"HistoSonics Secures $102M Series D Financing","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-stake-acquired-2b-investor-syndicate/","title":"HistoSonics stake acquired by $2B investor syndicate","sourceName":"MassDevice"},{"url":"https://www.businesswire.com/news/home/20250807749442/en/HistoSonics-Announces-%242.25B-Acquisition-by-Consortium-of-Top-Tier-Investors","title":"HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors","sourceName":"Business Wire"}],"keyFacts":[{"label":"HQ","value":"Plymouth, Minnesota, USA"},{"label":"Founded","value":"2009"},{"label":"CEO","value":"Mike Blue"},{"label":"Product","value":"Edison Histotripsy System, non-invasive focused ultrasound for tumor destruction."},{"label":"FDA","value":"De Novo authorization for liver tumors, Oct 2023; kidney indication pending."},{"label":"CE Mark (reported, Jul 2026)","value":"CE Mark granted."},{"label":"Ownership (Aug 2025)","value":"Management-led majority stake bought by K5 Global, Bezos Expeditions, Wellington; valued ~$2.25B."},{"label":"Funding (reported, unconfirmed)","value":"$102M+ Series D led by Alpha Wave Ventures."},{"label":"Valuation (reported, 2026)","value":"$3.75B"},{"label":"Investors","value":"Alpha Wave Ventures, Amzak Health, HealthQuest Capital, J&J Innovation."}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-23T13:40:08.115Z","updatedAt":"2026-10-21T00:50:33.687Z"},"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/histosonics-edison-newport-beach-california-usa","url":"https://registry.deploy.report/deployments/histosonics-edison-newport-beach-california-usa","name":"Edison Histotripsy System at Hoag Memorial Hospital Presbyterian","identifier":"ba09f92a-6b85-47e0-9264-25e22bd2c8f1","startDate":"2024-01-01T00:00:00.000Z","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/newport-beach-california-usa","name":"Hoag Memorial Hospital Presbyterian"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/histosonics","name":"HistoSonics"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/histosonics-edison","name":"Edison Histotripsy System"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"commercial","lifecycle_state":"active","architectural_position":{"cohort":"surgical","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}